The recent American Diabetes Association / European Association for the Study of Diabetes consensus panel produced their treatment algorithm to control glycaemia in type 2 diabetes. How can healthcare professionals treating patients with type 2 diabetes provide additional prandial intervention to reach A1c targets? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of North Carolina School of Medicine, Dr. John Buse, as they discuss the results of the glargine-exenatide combination study and its implications for a preferred treatment algorithm.
New Treatment Algorithm for Type 2 Diabetes
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
The recent American Diabetes Association / European Association for the Study of Diabetes consensus panel produced their treatment algorithm to control glycaemia in type 2 diabetes. How can healthcare professionals treating patients with type 2 diabetes provide additional prandial intervention to reach A1c targets? Join host Dr. Steven Edelman and his guest, professor of medicine at the University of North Carolina School of Medicine, Dr. John Buse, as they discuss the results of the glargine-exenatide combination study and its implications for a preferred treatment algorithm.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Medical Industry Feature
Digital Therapeutics Clinical Trials: From Design to Data Interpretation
<p>Digital Therapeutics Clinical Trials: From Design to Data Interpretation </p>
Medical Industry Feature
Engaging Patients and Caregivers About Digital Therapeutics
<p>Engaging Patients and Caregivers About Digital Therapeutics</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE Broadcast Replay
Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease
1.00 credits
<p>Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease</p>
CME/CE
IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement
0.50 credits
<p>IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement</p>
MinuteCE®
HF Management for Patients with Comorbid Conditions
0.75 credits
<p>HF Management for Patients with Comorbid Conditions</p>
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
0.50 credits
<p><span data-contrast="auto" xml:lang="EN-US">Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow</span><span data-ccp-props='{"201341983":0,"335559739":0,"335559740":240}'> </span></p>
CME/CE
Collaborative Insights to Solve the Puzzle of Bladder Cancer
1.00 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Collaborative Insights to Solve the Puzzle of Bladder Cancer</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?